Tech company CytoReason has announced it has signed a multi-year, multimillion dollar deal with Sanofi to deliver artificial intelligence (AI) for drug discovery and development in the fiel
Celltrion Healthcare’s subcutaneous (SC) formulation of its infliximab biosimilar, codenamed CT-P13 SC, looks set to launch in Europe in the coming months in rheumatoid arthritis, after a p
Takeda has proposed selling off a Shire treatment for inflammatory bowel disease when the companies merge next year, to avoid an overlap with its own drug.
Pfizer’s janus kinase (JAK) inhibitor drug Xeljanz (tofacitinib) has received expanded approval from the FDA for adults with moderately-to-severely-active ulcerative colitis.
Our website has served us well over the years, but after five years since the last re-design – during which aesthetic standards have changed and website technology has improved